Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golidocitinib in First-Line Peripheral T-Cell Lymphoma
NCT07032532Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of golidocitinib in peripheral T-cell lymphoma (PTCL), sponsored by Sun Yat-sen University. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
golidocitinib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT07032532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07032532.